Inhibition of Histone Deacetylase 6 Acetylates and Disrupts the Chaperone Function of Heat Shock Protein 90

Cited by (774)

Items 101–200 of 774

1. Targeting Histone Deacetylases for Cancer Therapy: From Molecular Mechanisms to Clinical Implications
   Zhiming Li, Wei‐Guo Zhu · 2014 · International Journal of Biological Sciences
2. Histone deacetylases: target enzymes for cancer therapy
   Denis Mottet, Vincent Castronovo · 2007 · Clinical & Experimental Metastasis
3. Cytotoxicity Mediated by Histone Deacetylase Inhibitors in Cancer Cells: Mechanisms and Potential Clinical Implications
   David S. Schrump · 2009 · Clinical Cancer Research
4. The histone deacetylase inhibitor ITF2357 selectively targets cells bearing mutated JAK2V617F
   Vittoria Guerini, Valentina Barbui, Orietta Spinelli, Aldo Salvi, Chiara Maria Dellacasa, Alessandra Carobbio, Martino Introna, Tiziano Barbui, Josée Golay, Alessandro Rambaldi · 2007 · Leukemia
5. Histone deacetylase inhibitors for the treatment of myelodysplastic syndrome and acute myeloid leukemia
   Alfonso Quintás‐Cardama, Fábio Pires de Souza Santos, Guillermo Garcia‐Manero · 2010 · Leukemia
6. Recent advances in the discovery of potent and selective HDAC6 inhibitors
   Wang, Xiu-Xiu, Wan, Ren-Zhong, Liu, Zhao-Peng · 2018 · European Journal of Medicinal Chemistry
7. Development of histone deacetylase inhibitors for cancer treatment
   Douglas C. Marchion, Pamela N. Münster · 2007 · Expert Review of Anticancer Therapy
8. Histone deacetylase inhibitors in hematological malignancies and solid tumors
   Pusoon Chun · 2015 · Archives of Pharmacal Research
9. HDAC6 Regulates Glucocorticoid Receptor Signaling in Serotonin Pathways with Critical Impact on Stress Resilience
   Julie Espallergues, Sarah L. Teegarden, Avin Veerakumar, Janette Boulden, Collin Challis, Jeanine Jochems, Michael Chan, Tess L. Petersen, Evan S. Deneris, Patrick Matthias et al. · 2012 · Journal of Neuroscience
10. Combined effects of novel tyrosine kinase inhibitor AMN107 and histone deacetylase inhibitor LBH589 against Bcr-Abl–expressing human leukemia cells
    Warren C. Fiskus, Michael Pranpat, Purva Bali, Maria E. Balasis, Sandhya Kumaraswamy, Sandhya Boyapalle, Kathy Rocha, Jie Wu, Francis Joseph Giles, Paul William Manley et al. · 2006 · Blood
11. Histone deacetylase inhibitors: potential targets responsible for their anti-cancer effect
    Michael John Dickinson, Ricky W. Johnstone, Henry Miles Prince · 2010 · Investigational New Drugs
12. Endogenous modulators and pharmacological inhibitors of histone deacetylases in cancer therapy
    Sarah Spiegel, Sheldon Milstien, Steven Grant · 2011 · Oncogene
13. Hydroxamic Acid Analogue Histone Deacetylase Inhibitors Attenuate Estrogen Receptor-α Levels and Transcriptional Activity: A Result of Hyperacetylation and Inhibition of Chaperone Function of Heat Shock Protein 90
    Warren C. Fiskus, Yuan Ren, Alex Mohapatra, Purva Bali, Aditya Mandawat, Rekha Rao, Bryan E. Herger, Yonghua Yang, Peter Wisdom Atadja, Jie Wu et al. · 2007 · Clinical Cancer Research
14. The Tale of Protein Lysine Acetylation in the Cytoplasm
    Karin Sadoul, Jin Wang, Boubou Diagouraga, Saadi Khochbin · 2010 · BioMed Research International
15. Phase Ia/II, two-arm, open-label, dose-escalation study of oral panobinostat administered via two dosing schedules in patients with advanced hematologic malignancies
    Daniel J. DeAngelo, Andrew G Spencer, Kapil N. Bhalla, Henry Miles Prince, T Fischer, Thomas Kindler, Francis Joseph Giles, Jeffrey W. Scott, Kathryn Parker, A Liu et al. · 2013 · Leukemia
16. Acetylation Goes Global: The Emergence of Acetylation Biology
    Kristi L. Norris, Joo‐Yong Lee, Tso‐Pang Yao · 2009 · Science Signaling
17. Gene and Protein Expression Profiling of Human Ovarian Cancer Cells Treated with the Heat Shock Protein 90 Inhibitor 17-Allylamino-17-Demethoxygeldanamycin
    Alison Maloney, Paul Andrew Clarke, Søren Naaby‐Hansen, Robert C. Stein, Jens-Oliver Koopman, Akunna Akpan, Alice Yang, Marketa Zvelebil, Rainer Cramer, Lindsay Stimson et al. · 2007 · Cancer Research
18. HDAC6 α-tubulin deacetylase: A potential therapeutic target in neurodegenerative diseases
    Guoyi Li, Huiyi Jiang, Ming Chang, Hongrong Xie, Linsen Hu · 2011 · Journal of the Neurological Sciences
19. Histone deacetylase 1, 2, 6 and acetylated histone H4 in B‐ and T‐cell lymphomas
    Lena Marquard, Christian Bjørn Poulsen, Lise Mette Rahbek Gjerdrum, Peter de Nully Brown, Ib Jarle Christensen, Peter Buhl Jensen, Maxwell Sehested, Preben Johansen, Elisabeth Methner Ralfkiaer · 2009 · Histopathology
20. Vorinostat-An overview
    AdityaKumar Bubna · 2015 · Indian Journal of Dermatology
21. Hsp90 regulates tau pathology through co-chaperone complexes in Alzheimer's disease
    Antero Salminen, Johanna O. Ojala, Kai Kaarniranta, Mikko Hiltunen, Hilkka S. Soininen · 2010 · Progress in Neurobiology
22. Development and Therapeutic Implications of Selective Histone Deacetylase 6 Inhibitors
    Jay H. Kalin, Joel A. Bergman · 2013 · Journal of Medicinal Chemistry
23. Inhibition of Histone Deacetylase Class I but not Class II Is Critical for the Sensitization of Leukemic Cells to Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand–Induced Apoptosis
    Satoshi Inoue, Antonello Mai, Martin J.S. Dyer, Gerald M. Cohen · 2006 · Cancer Research
24. Loss of HDAC6, a novel CHIP substrate, alleviates abnormal tau accumulation
    Casey N. Cook, Tania F. Gendron, Kristyn Scheffel, Yari Carlomagno, Judy H. Dunmore, Michael A. Deture, Leonard Petrucelli · 2012 · Human Molecular Genetics
25. Genistein down-regulates androgen receptor by modulating HDAC6-Hsp90 chaperone function
    Shashwati Basak, Deepa Pookot, Emily J. Noonan, Rajvir Dahiya · 2008 · Molecular Cancer Therapeutics
26. Histone deacetylase inhibitors: gathering pace
    N CAREY, Nicholas Barrie La Thangue · 2006 · Current Opinion in Pharmacology
27. Effect of the histone deacetylase inhibitor LBH589 against epidermal growth factor receptor–dependent human lung cancer cells
    Arthur Edwards, Jiannong Li, Peter Wisdom Atadja, Kapil N. Bhalla, Eric B. Haura · 2007 · Molecular Cancer Therapeutics
28. Microtubule acetylation amplifies p38 kinase signalling and anti-inflammatory IL-10 production
    Bin Wang, Yan-Hua Rao, Makoto Inoue, Rui Hao, Chun-Hsiang Lai, David J. Chen, Stacey L. McDonald, Moon-Chang Choi, Qiu Wang, Mari L. Shinohara et al. · 2014 · Nature Communications
29. HDAC6 regulates androgen receptor hypersensitivity and nuclear localization via modulating Hsp90 acetylation in castration-resistant prostate cancer.
    Ai, Junkui, Wang, Yujuan, Dar, Javid A., Liu, June, Liu, Lingqi, Nelson, Joel B., Wang, Zhou · 2009 · Molecular Endocrinology
30. Histone Deacetylase 6 Regulates Human Immunodeficiency Virus Type 1 Infection
    Agustı́n Valenzuela-Fernández, Susana Álvarez, Mónica Gordón‐Alonso, Marta Barrero-Villar, Ángeles Ursa, José Román Cabrero, Gerónimo Fernández, Salvador Naranjo‐Suarez, María Yáñez‐Mó, Juan Manuel Serrador et al. · 2005 · Molecular Biology of the Cell
31. Histone deacetylases and epigenetic therapies of hematological malignancies
    Ciro Mercurio, Saverio Minucci, Pier Giuseppe Pelicci · 2010 · Pharmacological Research
32. Lysine Deacetylases Hda1 and Rpd3 Regulate Hsp90 Function thereby Governing Fungal Drug Resistance
    Robbins, Nicole, Leach, Michelle D., Cowen, Leah E. · 2012 · Cell Reports
33. Inhibition of HDAC6 Deacetylase Activity Increases Its Binding with Microtubules and Suppresses Microtubule Dynamic Instability in MCF-7 Cells
    Jayant Asthana, Sonia Kapoor, Renu Mohan, Dulal Panda · 2013 · Journal of Biological Chemistry
34. Old but Gold: Tracking the New Guise of Histone Deacetylase 6 (HDAC6) Enzyme as a Biomarker and Therapeutic Target in Rare Diseases
    Margherita Brindisi, Akella Prasanth Saraswati, Simone Brogi, Sandra Gemma, Stefania Butini, Giuseppe Campiani · 2019 · Journal of Medicinal Chemistry
35. Heat shock proteins as gatekeepers of proteolytic pathways—Implications for age-related macular degeneration (AMD)
    Kai Kaarniranta, Antero Salminen, Eeva‐Liisa Eskelinen, Jürgen Kopitz · 2009 · Ageing Research Reviews
36. Ubiquitin Proteasome System Stress Underlies Synergistic Killing of Ovarian Cancer Cells by Bortezomib and a Novel HDAC6 Inhibitor
    Martina Bazzaro, Zhenhua Lin, Antonio Santillan, Michael K. Lee, Mei‐Cheng Wang, Kwun Chuen Gary Chan, Robert E. Bristow, Ralph Mazitschek, James E. Bradner, Richard B. S. Roden · 2008 · Clinical Cancer Research
37. Apoptotic Sensitivity of Colon Cancer Cells to Histone Deacetylase Inhibitors Is Mediated by an Sp1/Sp3-Activated Transcriptional Program Involving Immediate-Early Gene Induction
    Andrew J. Wilson, Anderly C. Chüeh, Lars Tögel, Georgia A. Corner, Naseem Ahmed, Sanjay Goel, Do-Sun Byun, Shannon Nasser, Michele A. Houston, Minaxi P. Jhawer et al. · 2010 · Cancer Research
38. Phase I Pharmacokinetic and Pharmacodynamic Study of LAQ824, a Hydroxamate Histone Deacetylase Inhibitor with a Heat Shock Protein-90 Inhibitory Profile, in Patients with Advanced Solid Tumors
    Johann Sebastian De Bono, Rebecca Sophie Kristeleit, Anthony W. Tolcher, Peter C.C. Fong, Simon Pacey, Vasilios Karavasilis, Monica M Mita, Heather May Shaw, Paul Workman, Stan B. Kaye et al. · 2008 · Clinical Cancer Research
39. Recent progress on HDAC inhibitors with dual targeting capabilities for cancer treatment
    Xiaopeng Peng, Zhiqiang Sun, Peihua Kuang, Jianjun Chen · 2020 · European Journal of Medicinal Chemistry
40. Modulating molecular chaperone Hsp90 functions through reversible acetylation
    Sayura Aoyagi, Trevor Archer · 2005 · Trends in Cell Biology
41. Development of Selective Histone Deacetylase 6 (HDAC6) Degraders Recruiting Von Hippel–Lindau (VHL) E3 Ubiquitin Ligase
    Yang, Ka, Wu, Hao, Zhang, Zhongrui, Leisten, Eric D., Nie, Xueqing, Liu, Binkai, Wen, Zhi, Zhang, Jing, Cunningham, Michael D., Tang, Weiping · 2020 · ACS Medicinal Chemistry Letters
42. Phase II trial of the pan-deacetylase inhibitor panobinostat as a single agent in advanced relapsed/refractory multiple myeloma
    Jeffrey Lee Wolf, David Samuel DiCapua Siegel, Hartmut Goldschmidt, Katharine Hazell, Priscille M. Bourquelot, Bourras‐Rezki Bengoudifa, Jeffrey Matous, Ravi Vij, Margarida D. Magalhaes-Silverman, Rafat Abonour et al. · 2012 · Leukemia & lymphoma/Leukemia and lymphoma
43. The histone deacetylase inhibitors LAQ824 and LBH589 do not require death receptor signaling or a functional apoptosome to mediate tumor cell death or therapeutic efficacy
    Leigh Ellis, Michael L Bots, Ralph K. Lindemann, Jessica E. Bolden, Andrea Newbold, Leonie A. Cluse, Clare L. Scott, Andreas Strasser, Peter Wisdom Atadja, Scott W. Lowe et al. · 2009 · Blood
44. Synthesis and Biological Investigation of Oxazole Hydroxamates as Highly Selective Histone Deacetylase 6 (HDAC6) Inhibitors
    Johanna Senger, Jelena Melesina, Martin Marek, Christophe Romier, Ina Oehme, Olaf Witt, Wolfgang Sippl, Manfred Jung · 2015 · Journal of Medicinal Chemistry
45. Inhibiting the HSP90 chaperone destabilizes macrophage migration inhibitory factor and thereby inhibits breast tumor progression
    Ramona Schulz‐Heddergott, Natalia D. Marchenko, Lena Holembowski, Günter Fingerle‐Rowson, Marina Hadzi Pesic, Lars Zender, Matthias Dobbelstein, Ute Martha Moll · 2012 · The Journal of Experimental Medicine
46. HDAC6 Modulates Hsp90 Chaperone Activity and Regulates Activation of Aryl Hydrocarbon Receptor Signaling
    Vikram Dilip Kekatpure, Andrew J. Dannenberg, Kotha Subbaramaiah · 2009 · Journal of Biological Chemistry · Retracted
47. Dual Degradation of Aurora A and B Kinases by the Histone Deacetylase Inhibitor LBH589 Induces G2-M Arrest and Apoptosis of Renal Cancer Cells
    Tai‐Lung Cha, Mei‐Jen Chuang, Sheng‐Tang Wu, Guang‐Huan Sun, Sun‐Yran Chang, Dah‐Shyong Yü, Shih‐Ming Huang, Steven Kuan-Hua Huan, Tse‐Chou Cheng, Tzu‐Ting Chen et al. · 2009 · Clinical Cancer Research
48. How do tumor cells respond to HDAC inhibition?
    Andrea Newbold, Katrina J. Falkenberg, Henry Miles Prince, Ricky W. Johnstone · 2016 · FEBS Journal
49. JAK2 inhibitors for myeloproliferative neoplasms: what is next?
    Prithviraj Bose, Srđan Verstovšek · 2017 · Blood
50. Raf kinases: Oncogenesis and drug discovery
    Ralf Schreck, Ulf Rüdiger Rapp · 2006 · International Journal of Cancer
51. Prognostic significance of the therapeutic targets histone deacetylase 1, 2, 6 and acetylated histone H4 in cutaneous T-cell lymphoma
    Lena Marquard, Lise Mette Rahbek Gjerdrum, Ib Jarle Christensen, Peter Buhl Jensen, Maxwell Sehested, Elisabeth Methner Ralfkiaer · 2008 · Histopathology
52. The histone deacetylase inhibitor ITF2357 has anti-leukemic activity in vitro and in vivo and inhibits IL-6 and VEGF production by stromal cells
    Josée Golay, Lucia Cuppini, F. Leoni, Maria Caterina Micò, Valentina Barbui, M Domenghini, L. Tallone Lombardi, Antonino Neri, Anna Maria Barbui, Aldo Salvi et al. · 2007 · Leukemia
53. Histone deacetylases: salesmen and customers in the post‐translational modification market
    André Brandl, Thorsten Heinzel, Oliver Holger Krämer · 2009 · Biology of the Cell
54. Design, Synthesis, Structure−Selectivity Relationship, and Effect on Human Cancer Cells of a Novel Series of Histone Deacetylase 6-Selective Inhibitors
    Yukihiro Itoh, Takayoshi Suzuki, Akiyasu Kouketsu, Nobuaki Suzuki, Satoko Maeda, Minoru Yoshida, Hidehiko Nakagawa, Naoki Miyata · 2007 · Journal of Medicinal Chemistry
55. The pan-HDAC inhibitor vorinostat potentiates the activity of the proteasome inhibitor carfilzomib in human DLBCL cells in vitro and in vivo
    Girija Prasad Dasmahapatra, Dmitry Lembersky, Lora B. Kramer, Richard I. Fisher, Jonathan W. Friedberg, Paul Dent, Steven Grant · 2010 · Blood · Retracted
56. HDAC6 Deacetylates Ku70 and Regulates Ku70-Bax Binding in Neuroblastoma
    Chitra Subramanian, Jason A. Jarzembowski, Anthony W. Opipari, Valerie P. Castle, Roland P.S. Kwok · 2011 · Neoplasia
57. Highly Potent and Selective Histone Deacetylase 6 Inhibitors Designed Based on a Small-Molecular Substrate
    Takayoshi Suzuki, Akiyasu Kouketsu, Yukihiro Itoh, Shinya Hisakawa, Satoko Maeda, Minoru Yoshida, Hidehiko Nakagawa, Naoki Miyata · 2006 · Journal of Medicinal Chemistry
58. Deacetylation of Nonhistone Proteins by HDACs and the Implications in Cancer
    Lirong Peng, Edward Seto · 2011 · Handbook of experimental pharmacology
59. Inclusion body formation, macroautophagy, and the role of HDAC6 in neurodegeneration
    Christiane Richter‐Landsberg, Janina Leyk · 2013 · Acta Neuropathologica
60. A Novel Class of Small Molecule Inhibitors of HDAC6
    Elizabeth S. Inks, Benjamin John Josey, Sean R. Jesinkey, C. James Chou · 2011 · ACS Chemical Biology
61. Histone Deacetylase Inhibitors and Phenotypical Transformation of Cancer Cells
    Anna Wawruszak, Joanna Kałafut, Estera Okoń, Jakub Czapiński, Marta Hałasa, Alicja Przybyszewska-Podstawka, Paulina Anna Miziak, Karolina Okła, Adolfo Rivero‐Müller, Andrzej Stepulak · 2019 · Cancers
62. Histone Deacetylase Inhibitors as Novel Anticancer Therapeutics
    Donald R. Walkinshaw, Xuejia Yang · 2008 · Current Oncology
63. The novel histone de acetylase 6 inhibitor, MPT0G211, ameliorates tau phosphorylation and cognitive deficits in an Alzheimer’s disease model
    Sheng-Jun Fan, Fang-I Huang, Jing‐Ping Liou, Chia‐Ron Yang · 2018 · Cell Death and Disease
64. Berberine Suppresses Androgen Receptor Signaling in Prostate Cancer
    Jing Li, Bo Cao, Xichun Liu, Xueqi Fu, Zhenggang Xiong, Li Chen, Oliver A. Sartor, Yan Dong, Haitao Zhang · 2011 · Molecular Cancer Therapeutics
65. Cotreatment with Vorinostat (Suberoylanilide Hydroxamic Acid) Enhances Activity of Dasatinib (BMS-354825) against Imatinib Mesylate–Sensitive or Imatinib Mesylate–Resistant Chronic Myelogenous Leukemia Cells
    Warren C. Fiskus, Michael Pranpat, Maria E. Balasis, Purva Bali, Veronica C. Estrella, Sandhya Kumaraswamy, Rekha Rao, Kathy Rocha, Bryan E. Herger, Francis Y. Lee et al. · 2006 · Clinical Cancer Research
66. Advances in the discovery and development of heat-shock protein 90 inhibitors for cancer treatment
    Hardik Patel, Shanu Modi, Gabriela Chiosis, Tony Taldone · 2011 · Expert Opinion on Drug Discovery
67. Molecular Aspects of the Stress Response: Chaperones, Membranes and Networks
    Péter Csermely, László Vígh · 2007 · Springer eBooks
68. DNA microarray profiling of genes differentially regulated by the histone deacetylase inhibitors vorinostat and LBH589 in colon cancer cell lines
    LaBonte, Melissa J, Wilson, Peter M, Fazzone, William, Groshen, Susan, Lenz, Heinz-Josef, Ladner, Robert D · 2009 · BMC Medical Genomics
69. HDAC as onco target: Reviewing the synthetic approaches with SAR study of their inhibitors
    Rekha Sangwan, Remya Rajan, Pintu Kumar Mandal · 2018 · European Journal of Medicinal Chemistry
70. Panobinostat treatment depletes EZH2 and DNMT1 levels and enhances decitabine mediated de-repression of JunB and loss of survival of human acute leukemia cells
    Warren C. Fiskus, Kate Buckley, Rekha Rao, Aditya Mandawat, Yonghua Yang, Rajeshree Joshi, Yongchao Wang, Ramesh Balusu, Jianguang Chen, Sanjay Koul et al. · 2009 · Cancer Biology & Therapy
71. Class II histone deacetylases play pivotal roles in heat shock protein 90-mediated proteasomal degradation of vascular endothelial growth factor receptors
    Jung‐Hyun Park, Sung-Hak Kim, Moon-Chang Choi, Ju‐Hee Lee, Do‐Youn Oh, Seock‐Ah Im, Yung‐Jue Bang, Tae-You Kim · 2008 · Biochemical and Biophysical Research Communications
72. Therapeutic Options Against BCR-ABL1 T315I-Positive Chronic Myelogenous Leukemia
    Alfonso Quintás‐Cardama, Jörge E. Cortes · 2008 · Clinical Cancer Research
73. Regulation of molecular chaperones through post-translational modifications: Decrypting the chaperone code
    Philippe Cloutier, Benoit Coulombe · 2013 · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms
74. Selective pharmacological inhibitors of HDAC6 reveal biochemical activity but functional tolerance in cancer models
    Yves Depetter, Silke Geurs, Rob De Vreese, Sophie Goethals, Elien Vandoorn, Alien Laevens, Jonas Steenbrugge, Evelyne Meyer, Pascal De Tullio, Marc Bracke et al. · 2019 · International Journal of Cancer
75. Will broad-spectrum histone deacetylase inhibitors be superseded by more specific compounds?
    Tom C. Karagiannis, Assam El‐Osta · 2006 · Leukemia
76. Lymphocyte Chemotaxis Is Regulated by Histone Deacetylase 6, Independently of Its Deacetylase Activity
    Cabrero, J. Román, Serrador, Juan M., Barreiro, Olga, Mittelbrunn, María, Naranjo-Suárez, Salvador, Martín-Cófreces, Noa, Vicente-Manzanares, Miguel, Mazitschek, Ralph, Bradner, James E., Ávila, Jesús et al. · 2006 · Molecular Biology of the Cell
77. A chemical probe toolbox for dissecting the cancer epigenome
    Jake Shortt, Christopher J. Ott, Ricky W. Johnstone, James E. Bradner · 2017 · Nature reviews. Cancer
78. HDAC6: A unique HDAC family member as a cancer target
    Sumeet Kaur, Prerna Rajoria, Madhu Chopra · 2022 · Cellular Oncology
79. Activity of the histone deacetylase inhibitor belinostat (PXD101) in preclinical models of prostate cancer
    Xiaozhong Qian, Gulshan Ara, Evan Mills, William J. LaRochelle, Henri S. Lichenstein, Michael Jeffers · 2007 · International Journal of Cancer
80. PI3K/mTOR Inhibition Markedly Potentiates HDAC Inhibitor Activity in NHL Cells through BIM- and MCL-1–Dependent Mechanisms In Vitro and In Vivo
    Mohamed Rahmani, Mandy Mayo Aust, Elisa C. Benson, LaShanale M. Wallace, Jonathan W. Friedberg, Steven Grant · 2014 · Clinical Cancer Research
81. Histone Deacetylase 6 (HDAC6) Is an Essential Modifier of Glucocorticoid-Induced Hepatic Gluconeogenesis
    Robin Winkler, Verena Benz, Markus Clemenz, M Bloch, Anna Foryst‐Ludwig, Sami Wardat, Nicole Witte, Manuela Trappiel, Pawel Namsolleck, Knut Mai et al. · 2011 · Diabetes
82. Molecular Interaction Network of the Hsp90 Chaperone System
    Rongmin Zhao, Walid A. Houry · 2007 · Springer eBooks
83. α-Tubulin K40 acetylation is required for contact inhibition of proliferation and cell–substrate adhesion
    Andrea Aguilar, Lars Becker, Thomas R. Tedeschi, Stefan Heller, Carlo Iomini, Maxence V. Nachury · 2014 · Molecular Biology of the Cell
84. HDAC4 Controls Muscle Homeostasis through Deacetylation of Myosin Heavy Chain, PGC-1α, and Hsc70
    Liqing Luo, Sherry C. Martin, Jascha D. Parkington, Samuel M. Cadena, Jiang Zhu, Chikwendu Ibebunjo, Serge Summermatter, Nicole Londraville, Krystyna Patora‐Komisarska, Leo Widler et al. · 2019 · Cell Reports
85. The Hsp90 chaperone network modulates Candida virulence traits
    O’Meara, Teresa R., Robbins, Nicole, Cowen, Leah E. · 2017 · Trends in Microbiology
86. Histone deacetylase inhibitor induces cell apoptosis and cycle arrest in lung cancer cells via mitochondrial injury and p53 up-acetylation
    Lianmin Bao, Hua Diao, Nian Dong, Xiaoqiong Su, Bingbin Wang, Qiongya Mo, Heguo Yu, Xiangdong Wang, Chengshui Chen · 2016 · Cell Biology and Toxicology
87. R306465 is a novel potent inhibitor of class I histone deacetylases with broad-spectrum antitumoral activity against solid and haematological malignancies
    Janine Arts, Patrick R. Angibaud, Ann Mariën, Wim Floren, Boud Janssens, P King, Jacky Van Dun, Lut Janssen, Tamara Geerts, Robert W. Tuman et al. · 2007 · British Journal of Cancer
88. Dissecting the Biological Functions of Drosophila Histone Deacetylases by RNA Interference and Transcriptional Profiling
    Cristiana Foglietti, Gessica Filocamo, Enrico Cundari, Emanuele de Rinaldis, Armin Lahm, Riccardo Cortese, Christian Steinkühler · 2006 · Journal of Biological Chemistry
89. Inhibitors of Deacetylases Suppress Oncogenic KIT Signaling, Acetylate HSP90, and Induce Apoptosis in Gastrointestinal Stromal Tumors
    Thomas Mühlenberg, Yixiang Zhang, Andrew J. Wagner, Florian Grabellus, James E. Bradner, G. Taeger, Hauke Lang, Takahiro Taguchi, Martin Schüler, Jonathan Alfred Fletcher et al. · 2009 · Cancer Research
90. The Dual EGFR/HER2 Inhibitor Lapatinib Synergistically Enhances the Antitumor Activity of the Histone Deacetylase Inhibitor Panobinostat in Colorectal Cancer Models
    Melissa J. LaBonte, Peter M. Wilson, Will Fazzone, Jared Russell, Stan G. Louie, Anthony B. El-Khoueiry, Heinz‐Josef Lenz, Robert D. Ladner · 2011 · Cancer Research
91. Tubocapsenolide A, a Novel Withanolide, Inhibits Proliferation and Induces Apoptosis in MDA-MB-231 Cells by Thiol Oxidation of Heat Shock Proteins
    Wen-Ying Chen, Fang‐Rong Chang, Zih-You Huang, Jyun-Hong Chen, Yang‐Chang Wu, Chin‐Chung Wu · 2008 · Journal of Biological Chemistry
92. p53 at the Crossroads between Different Types of HDAC Inhibitor-Mediated Cancer Cell Death
    Maria Mrakovcic, Johannes Kleinheinz, Leopold F. Fröhlich · 2019 · International Journal of Molecular Sciences
93. Blocking Non-enzymatic Functions by PROTAC-Mediated Targeted Protein Degradation
    Donghuan Sun, Jing Zhang, Guoqiang Dong, Shipeng He, Chunquan Sheng · 2022 · Journal of Medicinal Chemistry
94. Phase I/II trial of vorinostat (SAHA) and erlotinib for non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations after erlotinib progression
    Noemı́ Reguart, Rafael Rosell, Felipe Cardenal, Andrés Felipe Cardona, Dolores Isla, Ramón Palmero, Teresa Morán, Christian Diego Rolfo, Maria Cinta Pallarès, Amelia Insa et al. · 2014 · Lung Cancer
95. Endoplasmic Reticulum Dysfunction in Alzheimer’s Disease
    Jieqiong Li, Jin‐Tai Yu, Teng Jiang, Lan Tan · 2014 · Molecular Neurobiology
96. Antimalarial Activity of the Anticancer Histone Deacetylase Inhibitor SB939
    Subathdrage D.M. Sumanadasa, Christopher D. Goodman, Andrew J. Lucke, Tina S. Skinner‐Adams, Ishani Sahama, Ashraful Haque, Tram Anh Do, Geoffrey Ian McFadden, David P. Fairlie, Katherine T. Andrews · 2012 · Antimicrobial Agents and Chemotherapy
97. Epigenetic alterations and advancement of treatment in peripheral T-cell lymphoma
    Ping Zhang, Mingzhi Zhang · 2020 · Clinical Epigenetics
98. Antimalarial and antileishmanial activities of histone deacetylase inhibitors with triazole-linked cap group
    Vishal Patil, William Guerrant, Po C. Chen, Berkley E. Gryder, Derek B. Benicewicz, Shabana Iqrar Khan, Babu Lal Tekwani, Adegboyega K. Oyelere · 2009 · Bioorganic & Medicinal Chemistry
99. The enhancement of antiproliferative and proapoptotic activity of HDAC inhibitors by curcumin is mediated by Hsp90 inhibition
    Chiara Giommarelli, Valentina Zuco, Enrica Favini, Claudio Pisano, Fabrizio Dal Piaz, Nunziatina De Tommasi, Franco Zunino · 2009 · Cellular and Molecular Life Sciences
100. New clinical developments in histone deacetylase inhibitors for epigenetic therapy of cancer
     Shundong Cang, Yuehua Ma, Delong Liu · 2009 · Journal of Hematology & Oncology